Free Trial

Harmony Biosciences (HRMY) Competitors

Harmony Biosciences logo
$31.86 -0.17 (-0.54%)
As of 12:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HRMY vs. ELAN, LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, AKRO, and PCVX

Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Harmony Biosciences vs. Its Competitors

Harmony Biosciences (NASDAQ:HRMY) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Harmony Biosciences currently has a consensus price target of $53.63, suggesting a potential upside of 68.90%. Elanco Animal Health has a consensus price target of $15.17, suggesting a potential upside of 3.70%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Harmony Biosciences is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Harmony Biosciences
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Elanco Animal Health
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are owned by institutional investors. 23.6% of Harmony Biosciences shares are owned by company insiders. Comparatively, 0.9% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Harmony Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.

Elanco Animal Health has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Harmony Biosciences$714.73M2.55$145.49M$2.6212.12
Elanco Animal Health$4.44B1.64$338M$0.7419.76

In the previous week, Elanco Animal Health had 15 more articles in the media than Harmony Biosciences. MarketBeat recorded 16 mentions for Elanco Animal Health and 1 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.90 beat Elanco Animal Health's score of 0.50 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Harmony Biosciences Very Positive
Elanco Animal Health Neutral

Harmony Biosciences has a net margin of 20.53% compared to Elanco Animal Health's net margin of 8.43%. Harmony Biosciences' return on equity of 24.32% beat Elanco Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Harmony Biosciences20.53% 24.32% 15.92%
Elanco Animal Health 8.43%7.54%3.57%

Summary

Harmony Biosciences beats Elanco Animal Health on 11 of the 17 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HRMY vs. The Competition

MetricHarmony BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.83B$2.90B$5.51B$8.92B
Dividend YieldN/A2.69%5.38%4.12%
P/E Ratio12.1621.4026.2119.84
Price / Sales2.55279.63415.30113.63
Price / Cash10.7341.8936.4957.06
Price / Book2.757.358.005.32
Net Income$145.49M-$55.05M$3.15B$248.42M
7 Day Performance0.57%2.02%1.72%2.50%
1 Month Performance-10.71%6.76%4.63%5.53%
1 Year Performance5.83%4.83%35.87%19.65%

Harmony Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HRMY
Harmony Biosciences
4.7944 of 5 stars
$31.86
-0.5%
$53.63
+68.3%
+5.3%$1.82B$714.73M12.12200Positive News
ELAN
Elanco Animal Health
2.3312 of 5 stars
$13.36
-0.7%
$15.17
+13.5%
+2.5%$6.64B$4.43B18.059,000
LEGN
Legend Biotech
2.4528 of 5 stars
$33.85
-0.4%
$76.20
+125.1%
-21.1%$6.22B$627.24M-57.372,609Positive News
TGTX
TG Therapeutics
3.7452 of 5 stars
$36.56
+1.5%
$40.80
+11.6%
+95.0%$5.80B$329M152.33290
GRFS
Grifols
4.1169 of 5 stars
$8.37
-4.6%
$10.30
+23.1%
+43.3%$5.75B$7.81B7.1523,822Analyst Downgrade
LNTH
Lantheus
4.3333 of 5 stars
$80.81
+2.0%
$130.50
+61.5%
-0.7%$5.59B$1.53B22.96700
TLX
Telix Pharmaceuticals
N/A$16.39
-4.4%
$22.00
+34.2%
N/A$5.54B$516.72M0.00N/AGap Down
High Trading Volume
NUVL
Nuvalent
3.7087 of 5 stars
$75.98
+1.3%
$115.50
+52.0%
+3.3%$5.46BN/A-17.3140Analyst Upgrade
Insider Trade
AXSM
Axsome Therapeutics
4.7553 of 5 stars
$101.65
+1.0%
$172.33
+69.5%
+27.1%$5.01B$385.69M-17.62380Positive News
Analyst Revision
AKRO
Akero Therapeutics
3.6042 of 5 stars
$54.03
-0.3%
$82.50
+52.7%
+122.0%$4.31BN/A-27.7130
PCVX
Vaxcyte
1.8768 of 5 stars
$33.25
+1.2%
$136.50
+310.5%
-57.2%$4.29BN/A-8.33160News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:HRMY) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners